Director of Investor Relations - Biotech - Waltham, MA

About Our Client

Our client is a global clinical stage biotechnology company focused on the development of innovative therapies addressing areas of high unmet medical need. With multiple near term clinical and regulatory milestones and a transition toward commercialization underway, the company is entering a critical phase of growth requiring enhanced engagement with the global investment community.

Reporting directly to the Chief Financial Officer, the Director of Investor Relations will hold a highly visible and execution focused role during a pivotal period in the company evolution. This individual will be responsible for shaping and delivering a clear and differentiated investment narrative by translating complex scientific, clinical, and regulatory data into compelling messaging for institutional investors and sell‑side analysts.

The role will act as a close partner to the CEO and CFO and will lead the full execution of the investor relations strategy. Main duties and responsibilities will include the following:

• Partner with the CEO and CFO to define and implement the investor relations strategy
• Serve as a primary point of contact for institutional investors, sell‑side analysts, and shareholders
• Own and continuously refine the investment thesis and equity story
• Lead day‑to‑day IR execution including earnings preparation, investor presentations, Q&A preparation, conferences, roadshows, and investor targeting
• Translate preclinical and clinical data, mechanisms of action, trial endpoints, statistical outcomes, safety profiles, and competitive positioning into clear investor‑focused messaging
• Support investor communications surrounding clinical readouts and regulatory milestones including submissions, advisory committees, and approvals
• Draft and coordinate scientific and financial content for investor decks, press releases, scripts, and IR website materials in alignment with finance, legal, and communications teams
• Build and maintain long‑term relationships with leading biotechnology investors and analysts
• Monitor peer companies, competitive landscape, clinical developments, regulatory changes, and sector trends
• Track analyst models, consensus expectations, and key valuation drivers, providing actionable insights to senior leadership
• Ensure all external communications comply with SEC and disclosure requirements including support for earnings releases and public filings
• Maintain ownership of IR infrastructure including website content, investor calendars, shareholder surveillance, and engagement analytics
• Support development of commercialization and launch‑related messaging in collaboration with commercial leadership
• Integrate scientific, clinical, financial, and commercial narratives into a cohesive and credible equity story

This is a pivotal role which requires regular travel to Europe, ± 50% of the time. When not traveling, part of the role can be HYBRID and there is an office close to Waltham, MA.

In return for a competitive remuneration package, the successful candidate will possess the following:

• Bachelor's degree
• Advanced degree in a scientific field such as PhD, MD, or PharmD
• MBA or equivalent finance training strongly preferred, CFA a plus
• 7+ years of relevant experience in investor relations, equity research, investment banking, or consulting within biotechnology or pharmaceuticals
• Strong understanding of clinical trial design, biostatistics, and FDA and EMA regulatory pathways
• Prior experience supporting public company disclosure and earnings cycles
• Proven ability to communicate complex scientific and clinical data to sophisticated investor audiences
• Strong understanding of biotechnology valuation drivers
• Executive presence with confidence engaging senior leadership and external stakeholders
• High attention to detail with strong cross‑functional collaboration skills

• $280,000 to $300,000 base salary
• Performance‑related annual bonus scheme
• A highly visible leadership role within a rapidly evolving clinical‑stage biotech company
• Direct exposure to C‑suite leadership and board‑level stakeholders
• Opportunity to shape the market narrative through key clinical and commercial milestones